awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q44065014-1CEECC19-33FD-4D47-A23C-4B2D4CD691E9
Q44065014-1CEECC19-33FD-4D47-A23C-4B2D4CD691E9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q44065014-1CEECC19-33FD-4D47-A23C-4B2D4CD691E9
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
P2860
Q44065014-1CEECC19-33FD-4D47-A23C-4B2D4CD691E9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q44065014-1CEECC19-33FD-4D47-A23C-4B2D4CD691E9
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4d7f4856b4e821db364f618ca87f778af3e72e7a
P2860
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.